Troy Bremer

Summary

Publications

  1. ncbi request reprint A multimarker model to predict outcome in tamoxifen-treated breast cancer patients
    Steven P Linke
    Prediction Sciences, La Jolla, California 92037, USA
    Clin Cancer Res 12:1175-83. 2006
  2. ncbi request reprint CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension
    Troy Bremer
    Prediction Sciences, 9404 Genesee Ave, Suite 210, La Jolla, CA 92037, USA
    Pharmacogenomics 7:271-9. 2006
  3. ncbi request reprint The pharmacogenetics of lithium response depends upon clinical co-morbidity
    Troy Bremer
    Prediction Sciences, Inc, San Diego, California, USA
    Mol Diagn Ther 11:161-70. 2007
  4. doi request reprint Prognostic marker profile to assess risk in stage I-III hormone receptor-positive breast cancer patients
    Troy M Bremer
    Prediction Sciences, La Jolla, CA 92037 1354, USA
    Int J Cancer 124:896-904. 2009
  5. ncbi request reprint Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
    Neil L Spector
    Department of Discovery Medicine and Clinical Pharmacology, GlaxoSmithKline, Five Moore Dr, Research Triangle Park, NC 27709 3398, USA
    J Clin Oncol 23:2502-12. 2005

Research Grants

Detail Information

Publications5

  1. ncbi request reprint A multimarker model to predict outcome in tamoxifen-treated breast cancer patients
    Steven P Linke
    Prediction Sciences, La Jolla, California 92037, USA
    Clin Cancer Res 12:1175-83. 2006
    ..This study was designed to produce a model to predict outcome in tamoxifen-treated breast cancer patients based on clinicopathologic features and multiple molecular markers...
  2. ncbi request reprint CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension
    Troy Bremer
    Prediction Sciences, 9404 Genesee Ave, Suite 210, La Jolla, CA 92037, USA
    Pharmacogenomics 7:271-9. 2006
    ..Three SNPs in CANCA1C had significant associations with antihypertensive outcome, combining to yield a positive treatment outcome of less than 15 to 80%...
  3. ncbi request reprint The pharmacogenetics of lithium response depends upon clinical co-morbidity
    Troy Bremer
    Prediction Sciences, Inc, San Diego, California, USA
    Mol Diagn Ther 11:161-70. 2007
    ..A test that could predict response to lithium based upon genetic factors would have significant clinical value...
  4. doi request reprint Prognostic marker profile to assess risk in stage I-III hormone receptor-positive breast cancer patients
    Troy M Bremer
    Prediction Sciences, La Jolla, CA 92037 1354, USA
    Int J Cancer 124:896-904. 2009
    ..In summary, the profile intelligently combines biologically relevant marker pathways and established clinicopathologic risks to help guide breast cancer patients to the most appropriate level of adjuvant therapy...
  5. ncbi request reprint Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
    Neil L Spector
    Department of Discovery Medicine and Clinical Pharmacology, GlaxoSmithKline, Five Moore Dr, Research Triangle Park, NC 27709 3398, USA
    J Clin Oncol 23:2502-12. 2005
    ..This was a pilot study to assess the biologic effects of lapatinib on various tumor growth/survival pathways in patients with advanced ErbB1 and/or ErbB2-overexpressing solid malignancies...

Research Grants1

  1. SNP-based lithium treatment outcome diagnostic
    Troy Bremer; Fiscal Year: 2007
    ....